| Excerpt | Reference |
|---|
| "Therefore, single modality therapy for soft tissue sarcomas by operation alone results in an unacceptably high incidence of treatment failure." | ( Eilber, FR; Mirra, JM; Morton, DL; Townsend, CM; Weisenburger, TH, 1978) |
| "The treatment of soft tissue sarcomas in children at the Joint Center for Radiation Therapy, Children's Hospital Medical Center, and the Sidney Farber Cancer Institute from 1970 to 1976 has been reviewed." | ( Cassady, JR; Dritschilo, A; Filler, RM; Green, D; Jaffe, N; Paed, D; Weichselbaum, R, 1978) |
| "Comparison of the recurrence rates of soft tissue sarcomas treated by radiotherapy (14 patients) or radiotherapy and synchronous administration of razoxane (19 patients) has shown a statistically significant benefit for those patients treated by the combination." | ( Hellmann, K; James, SE; Jones, S; Macdonald, E; Newton, KA; Ryall, RD, 1978) |
| "Polychemotherapy for soft tissue sarcomas has been reported to produce response rates ranging from 24--60% (1, 2)." | ( Ahmann, DL; Bisel, HF; Creagan, ET; Eagan, RT; Edmonson, JH; Hahn, RG, 1978) |
| "The results of surgical treatment of 297 soft tissue sarcomas arising in the lower extremity were critically examined." | ( Castro, EB; Fortner, JG; Hajdu, SI; Shiu, MH, 1975) |
| "In the first German soft tissue sarcoma (STS) study, CWS-81, 344 patients younger than 19 years of age who had previously untreated soft tissue sarcoma were studied." | ( Bernhard, G; Bürger, D; Herbst, M; Jürgens, H; Keim, M; Koscielniak, E; Treuner, J; Winkler, K, 1992) |
| "Thirty-seven patients with advanced soft tissue sarcoma were treated with merbarone utilizing a daily intravenous schedule for five days." | ( Balcerzak, SP; Bendetti, J; Doroshow, JH; Kraut, EH, 1992) |
| "10 patients with refractory or relapsed soft tissue sarcoma were treated with weekly etoposide (150 mg/m2 on days 1, 2 and 3) and cisplatin (60 mg/m2 on day 2)." | ( Phillips, MB; Pinkerton, CR, 1992) |
| "Thirteen patients with soft tissue sarcomas were treated with a combination of intra-arterial Adriamycin, conventionally fractionated radiotherapy (2 Gy per day), and conservative surgery (trimodal therapy)." | ( Harmer, C; Mason, M; Robinson, M; Westbury, G, 1992) |
| "Adjuvant chemotherapy for patients with soft tissue sarcoma is investigational." | ( Brennan, MF; Casper, ES; Friedrich, C; Gaynor, JJ; Hajdu, SI; Magill, GB; Tan, C, 1991) |
| "Forty-three children with malignant soft tissue sarcomas (IRS Groups II-IV) were treated with rapid dose delivery chemotherapy protocol comprising six courses of vincristine, adriamycin and cyclophosphamide, given in most cases within 8 weeks (Rapid VAC)." | ( Ashley, S; Barrett, A; Groot-Loonen, J; McElwain, TJ; Meller, ST; Pinkerton, CR; Tait, D, 1991) |
| "Two thirds of soft tissue sarcomas of the extremities are primarily subcutaneous or intramuscular tumors, the majority of which can be treated by local surgery without local adjuvant therapy with a local recurrence rate of less than 10%, irrespective of malignancy grade." | ( Akerman, M; Alvegård, T; Gustafson, P; Herrlin, K; Rööser, B; Rydholm, A; Willén, H, 1991) |
| "The treatment of soft tissue sarcoma of the limb by function-saving resection and brachytherapy (BRT) was systematically studied from 1975 to 1990 at the Memorial Sloan-Kettering Cancer Center, using iridium-192 temporary tumor-bed implants." | ( Brennan, MF; Harrison, LB; Hilaris, BS; Shiu, MH, 1991) |
| "Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990." | ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990) |
| "Seventy-eight patients with soft tissue sarcoma (STS) arising in the distal extremities--wrist, hand, finger, ankle, foot, and toe--who were treated with conservation surgery and radiation therapy were studied retrospectively with respect to survival, local recurrence, functional limb preservation, complications, and distant metastasis." | ( Romsdahl, MM; Sherman, NE; Talbert, ML; Zagars, GK, 1990) |
| "On the other hand, soft tissue sarcoma has a variety of histological type and malignancy and the sensitivity to chemotherapy varies considerably according to each tissue type." | ( Shinohara, N; Yokoyama, K, 1990) |
| "Patients with objectively measurable soft tissue sarcoma, bone sarcoma, or mesothelioma who had failed at least one prior chemotherapy regimen received either bleomycin (20 U/M2 i." | ( Amato, DA; Borden, EC; Davis, HL; Enterline, HT; Lerner, HJ; Paul, AR; Rosenbaum, C; Shiraki, M; Stevens, CM, 1985) |
| "In the subset of soft tissue sarcomas, the response rate for the patients receiving bolus administration was 26%, compared with 9% for the patients receiving a continuous infusion schedule (P = ." | ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989) |
| "Sixty-three patients with soft tissue sarcomas of the limbs received postoperative radiotherapy during the period from 1969 to 1985." | ( Bistolfi, F; Grillo Ruggieri, F; Marziano, C, 1989) |
| "The treatment response rate of soft tissue sarcomas in the randomized study of Adriamycin (Adria Laboratories, Columbus, OH) regimens was slightly higher for those with lower grade sarcomas, i." | ( Amato, DA; Borden, EC; Brooks, JJ; Cooper, NS; Enterline, HT; Enzinger, FM; Hirschl, S; Rao, UN; Roth, JA; Shiraki, M, 1989) |
| "Forty-four patients were treated for soft tissue sarcoma of the lower extremity." | ( Biemer, E; Steinau, HU, 1988) |
| "Fifty-four patients with advanced soft tissue sarcoma were treated with a combination of ifosfamide (5 g/m2) and adriamycin (40-60 mg/m2) at 3 weekly intervals." | ( Fisher, C; King, M; MacMillan, S; Mansi, JL; Stuart-Harris, R; Wiltshaw, E, 1988) |
| "Twenty-six patients with soft tissue sarcomas of the forearm and hand were treated with limb salvage protocols involving surgical wide excision, chemotherapy, and radiation therapy." | ( Eilber, FR; Miller, TA; Wexler, AM, 1988) |
| "A limited number of patients with soft tissue sarcomas achieving a complete response with chemotherapy, will probably be cured, and for this reason it is important to aim at achieving a complete response." | ( Pinedo, HM; Verweij, J, 1986) |
| "Seven cases of soft tissue sarcoma developing after primary or postoperative radiotherapy for breast carcinoma are reported." | ( Borovik, R; Cohen, Y; Haim, N; Kuten, A; Robinson, E; Sapir, D, 1985) |
| "Bone and soft tissue sarcomas have rarely been observed after treatment of Hodgkin's disease, and only a few cases are described in the literature." | ( Banfi, A; Zanini, M; Zucali, R, 1983) |
| "Fourteen adult patients with inoperable soft tissue sarcoma (with metastases in 4 cases) received chemotherapy as primary treatment." | ( Amiel, JL; Carde, P; Contesso, G; Génin, J; Le Chevalier, T; Rouëssé, J; Sarrazin, D; Sevin, D, 1983) |
| "Sixty-five patients with high-grade soft tissue sarcomas of the extremities were treated in a prospective randomized trial evaluating the efficacy of adjuvant chemotherapy with doxorubicin, cyclophosphamide, and high-dose methotrexate." | ( Baker, A; Brennan, MF; Costa, J; Demoss, EV; Glatstein, E; Rosenberg, SA; Seipp, C; Sindelar, WF; Sugarbaker, P; Tepper, J; Wesley, R; Young, R, 1983) |
| "Thirty-four patients with advanced soft tissue sarcoma were treated with a three-drug combination including vindesine sulfate (DVA), Adriamycin, and cyclophosphamide (DAC) (S9)." | ( Brenner, J; Magill, GB; Sordillo, PP; Wissel, P, 1983) |
| "Eighty-three patients with advanced soft tissue sarcoma who had received no prior chemotherapy entered a randomised phase II study comparing carminomycin (CMM) 20 mg/m2 with adriamycin (ADM) 75 mg/m2, both administered i." | ( Bramwell, VH; Markham, D; Mouridsen, HT; Mulder, JH; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, AT, 1983) |
| "Fifty-one patients with soft tissue sarcoma of the extremities were treated by intra-arterial infusion chemotherapy with either VCQ (Vincristine and Carbazilquinone) or VCQ, A (Vincristine, Carbazilquinone and Adriamycin)." | ( Beppu, Y; Fukuma, H; Nishikawa, K, 1984) |
| "Patients with documented untreated soft tissue sarcoma of the lower limb are given continuous intra-arterial regional infusion with adriamycin consecutively for 8 days up to a dose of 100 mg/m2." | ( Andreola, S; Audisio, RA; Azzarelli, A; Bonfanti, G; Gennari, L; Quagliuolo, V, 1983) |
| "Eleven patients with advanced soft tissue sarcoma were treated with whole body hyperthermia (41." | ( Aisner, J; Ashman, M; Foy, J; Gerad, H; Helrich, M; Ostrow, S; van Echo, DA; Whitacre, M; Wiernik, PH, 1984) |
| "One hundred and one soft tissue sarcoma patients from an adjuvant chemotherapy study of the Surgery Branch, National Cancer Institute who had received greater than or equal to 430 mg/m2 (range, 430-600 mg/m2) of doxorubicin were followed for evidence of cardiomyopathy." | ( Barr, L; Bonow, RO; D'Angelo, T; Dresdale, A; Mathison, D; Palmeri, ST; Rosenberg, SA; Wesley, R, 1983) |
| "A total of 105 consecutive patients with soft tissue sarcomas (65 patients) or bone sarcomas (40 patients) were treated with preoperative intraarterial adriamycin, 3500 rads of rapid-fraction radiation and radical en bloc resection of primary tumor." | ( Eilber, FR; Grant, TT; Mirra, JJ; Morton, DL; Weisenburger, T, 1980) |
| "Patients with objectively measurable soft tissue sarcomas, osteosarcomas, chondrosarcomas, and mesotheliomas were treated with dibromodulcitol (DBD) (180 mg/m2 p." | ( Ash, A; Borden, EC; Enterline, HT; Falkson, G; Laucius, JF; Lerner, H; Paul, AR; Rosenbaum, C, 1982) |
| "Of 12 adult patients with high-grade soft tissue sarcoma receiving adjuvant chemotherapy and at risk for 36-84 months, 9 (75%) remain metastasis free and 10 (83%) have adequate local disease control with limb preservation." | ( Mills, EE, 1982) |
| "The medical treatment of advanced soft tissue sarcomas in adults is reviewed." | ( Beretta, G; Fraschini, P; Tedeschi, L, 1980) |
| "In 7 patients with bone and soft tissue sarcoma super-selective angiography with chemotherapy was performed." | ( Schepke, P; Wopfner, F, 1982) |
| "Sixty-two patients with metastatic soft tissue sarcomas of various histological types were treated with Cyvadic." | ( Hossfeld, DK; Schmidt, CG; Seeber, S; Siemers, E, 1981) |
| "21 patients with soft tissue sarcomas were treated after surgery with adriamycin alone or in combination with other drugs." | ( Brunner, KW; Goldhirsch, A; Tièche, M, 1980) |
| "In advanced soft tissue sarcomas of adults, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared." | ( Buesa, J; Casali, P; Mouridsen, H; Rankin, E; Santoro, A; Somers, R; Spooner, D; Steward, W; Tursz, T; Verweij, J, 1995) |
| "Twenty three patients with paediatric soft tissue sarcomas who had relapsed or refractory disease were treated with a rapid schedule of intravenous etoposide (100 mg/m2 daily on three consecutive days, weekly over 3 weeks)." | ( Flamant, F; Phillips, MB; Pinkerton, CR; Sommelet-Olive, D, 1995) |
| "Inoperable locally recurrent soft tissue sarcomas (STS) are incurable with chemotherapy." | ( Bodurtha, A; Boos, G; Bramwell, V; Eisenhauer, E; Knowling, M; Quirt, I, 1994) |
| "Nine patients with soft tissue sarcomas underwent pretreatment pO2 measurements with the Eppendorf pO2 histograph." | ( Brizel, DM; Dewhirst, MW; Harrelson, J; Prosnitz, LR; Rosner, GL, 1994) |
| "Based on our limited experience, epithelioid sarcoma of the orbit may have a course similar to that which occurs elsewhere in the body, requiring aggressive surgical treatment at the outset." | ( Freeman, JL; Heathcote, JG; Hurwitz, JJ; Rootman, J; White, VA, 1994) |
| "In 29 patients (9 breast carcinomas, 8 soft tissue sarcomas, 8 lymph node metastases of head and neck cancers and 4 different other tumors) the oxygenation status was examined before, during and after radio- and partially thermoradiotherapy." | ( Feldmann, HJ; Füller, J; Molls, M; Sack, H, 1994) |
| "Adjuvant chemotherapy for patients with soft tissue sarcoma remains investigational." | ( Brennan, MF; Casper, ES; Gaynor, JJ; Hajdu, SI; Harrison, LB; Panicek, DM, 1994) |
| "Locoregional control of soft tissue sarcomas of the limbs is achieved generally using a multidisciplinary approach consisting of conservative surgery combined with radiation therapy, intraarterial chemotherapy, or hyperthermic antiblastic perfusion (HAP)." | ( Foletto, M; Fornasiero, A; Lise, M; Melanotte, P; Ninfo, V; Nitti, D; Rossi, CR; Sotti, G; Tregnaghi, A; Vecchiato, A, 1994) |
| "The role of chemotherapy for soft tissue sarcoma with the exception of rhabdomyosarcoma remains controversial." | ( Hatakeyama, K; Ishii, T; Umeda, T; Wakita, H, 1993) |
| "Forty patients with soft tissue sarcoma (Enneking's stage I and II) were treated in our department between 1965 and 1992." | ( Hamada, M; Inoue, H; Nakagawa, Y; Ozaki, T; Sugihara, S, 1993) |
| "Nine children with soft tissue sarcomas, five of them rhabdomyosarcomas with initial metastatic disease, (one patient, partial response, one patient), refractory primary, (two patients, relapse, five patients) were treated with a combination of high-dose VP16 (100 mg/m2 daily for 5 days) and cisplatin (40 mg/m2 daily for 5 days)." | ( Bouffet, E; Bouhour, D; Brunat-Mentigny, M; Carrie, C; Frappaz, D; Grabois, M; Philip, T, 1994) |
| "These results indicate that soft tissue sarcomas often respond dramatically to chemotherapy, that the amount of residual viable sarcoma is an indicator of short-term effect, and that flow cytometric estimates of cell proliferation predict early response to chemotherapy." | ( Collins, C; Conrad, EU; Finney, A; Rabinovitch, P; Schmidt, RA, 1993) |
| "For patients with soft tissue sarcomas of the extremities, intraoperative radiotherapy was performed after the tumours were surgically removed to the greatest e* possible." | ( Abe, M; Nishimura, Y; Sasai, K; Shibamoto, Y; Takahashi, M, 1996) |
| "The role and value of chemotherapy for soft tissue sarcomas remain unclear." | ( Kito, M; Umeda, T, 1998) |
| "Ifosfamide is a leading drug in soft tissue sarcoma therapy." | ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998) |
| "The first chemotherapy study of soft tissue sarcoma (STS) by the Scandinavian Sarcoma Group was started in 1981 (SSG I)." | ( Alvegård, TA; Fernberg, JO; Hall, KS; Monge, O; Saeter, G; Strander, H; Wiklund, T, 1999) |
| "Adjuvant chemotherapy for soft tissue sarcoma has been the subject of many studies." | ( Seynaeve, C; Verweij, J, 1999) |
| "The goal of the second German Soft Tissue Sarcoma Study CWS-86 (1985 to 1990) was to improve the prognosis in children and adolescents with soft tissue sarcoma by means of a clinical trial comprising intensive chemotherapy and risk-adapted local therapy." | ( Gadner, H; Harms, D; Henze, G; Herbst, M; Jürgens, H; Klingebiel, T; Knietig, R; Koscielniak, E; Morgan, M; Schmidt, BF; Treuner, J, 1999) |
| "Advanced soft tissue sarcomas (ASTS) refractory to therapy with doxorubicin and/or ifosfamide are highly resistant to therapy with other cytotoxic agents." | ( Blay, JY; Hermans, C; Judson, I; Rodenhuis, S; Smith, M; van Glabbeke, M; Verweij, J, 1999) |
| "Conservative treatment of soft tissue sarcomas most often implies combination of surgical resection and irradiation." | ( Bonnevialle, P; Bui, BN; Chevreau, C; Daly-Schveitzer, N; Delannes, M; Kantor, G; Martel, P; Pigneux, J; Stoeckle, E; Thomas, L, 2000) |
| "Docetaxel is inactive in soft tissue sarcomas and cannot be recommended for further use in treatment of this disease." | ( Buesa, J; Coleman, R; di Paola, ED; Judson, IR; Lee, SM; Ruka, W; Seynaeve, C; Tonelli, D; van Glabbeke, M; van Hoessel, R; Verweij, J, 2000) |
| "Four patients with advanced soft tissue sarcomas were treated by selective intra-arterial injection of carboplatin (450 mg/m2/2 hr) and etoposide (200 mg/m2/2 hr)." | ( Hamana, T; Miyagi, N; Takahashi, M, 2000) |
| "Patients with metastatic or recurrent soft tissue sarcoma who had received no prior chemotherapy for advanced disease were treated with liposomal doxorubicin (Doxil) according to a two stage accrual design." | ( Budd, GT; Bukowski, R; Chidiac, T; Crownover, R; Elson, P; Joyce, M; Marks, K; McLain, D; Muschler, G; Pelley, R; Sandstrom, K; Zehr, R, 2000) |
| "Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation." | ( Bejkos, D; Bischof-Delaloye, A; Chassot, PG; Chiolero, R; Genton, A; Guillou, L; Landry, M; Lejeune, FJ; Leyvraz, PF; Leyvraz, S; Liénard, D; Mirimanoff, RO; Mosimann, F; Pujol, N; Raffoul, W, 2000) |
| "Post-contrast MR imaging of 36 soft tissue sarcomas performed 0-54 days (median 13 days) after pre-operative radiotherapy, were retrospectively reviewed and compared to post-operative histopathology reports." | ( Bauer, HC; Einarsdottir, H; Wejde, J, 2001) |
| "Adjuvant chemotherapy for soft tissue sarcoma is controversial because previous trials reported conflicting results." | ( Apice, G; Azzarelli, A; Barbieri, E; Bonetti, M; Buonadonna, A; Comandone, A; De Paoli, A; Frustaci, S; Gherlinzoni, F; Olmi, P; Picci, P; Pignatti, G; Serraino, D; Zmerly, H, 2001) |
| "Twenty-nine pretreated, advanced soft tissue sarcoma (STS) and bone sarcoma patients consecutively seen in our centers were included, 12 from a phase I trial and 17 from a compassionate use program cohort." | ( Brain, E; Cottu, P; Cvitkovic, E; Delaloge, S; Goldwasser, F; Jimeno, J; Marty, M; Misset, JL; Raymond, E; Riofrio, M; Taamma, A; Yovine, A, 2001) |
| "For high-risk soft tissue sarcoma (HR-STS) of adults new treatment strategies are needed to improve outcome with regard to local control and overall survival." | ( Issels, RD; Schlemmer, M, 2002) |
| "Ten patients with advanced soft tissue sarcoma and 5 patients after surgical resection were treated with HDI administered by continuous infusion at a dose of 14 g/m2 per cycle over 6 days." | ( Chen, LK; Liang, Y; Liu, JL; Teng, XY; Xu, GC; Zhou, XM, 2002) |
| "Sensitivity of human soft tissue sarcoma (STS) cells to methotrexate, doxorubicin, and paclitaxel was examined after cells were pretreated with CH-11, an agonistic anti-Fas antibody." | ( Bertino, JR; Li, W, 2002) |
| "The efficacy of chemotherapy for soft tissue sarcoma, including high-dose ifosfamide and cisplatin, has not been established yet." | ( Hatano, H; Hotta, T; Kawashima, H; Morita, T; Ogose, A; Ueda, T; Yazawa, Y, 2003) |
| "For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival." | ( Issels, RD; Schlemmer, M; Wendtner, CM, 2003) |
| "In the future PET imaging in bone and soft tissue sarcomas should be directed to the clinical implication for the detection and grading of sarcomas and the treatment evaluation of locally advanced sarcomas." | ( Bastiaannet, E; Cobben, DC; Groen, H; Hoekstra, HJ; Jager, PL; Vaalburg, W; van der Graaf, WT, 2004) |
| "Thirty-six previously treated soft tissue sarcoma patients from three institutions received ET-743 as a 24-hour continuous intravenous (IV) infusion at a dose of 1,500 microg/m(2) every 3 weeks." | ( Canniff, J; Demetri, GD; Garcia-Carbonero, R; Gomez, J; Goss, G; Guzman, C; Harmon, D; Jimeno, J; Lopez, T; Maki, RG; Manola, J; Matulonis, U; Merriam, P; Puchalski, TA; Quigley, MT; Ryan, DP; Sancho, MA; Seiden, MV; Supko, JG, 2004) |
| "Treatment for extremity soft tissue sarcoma (STS) has shifted in recent years from amputation to local wide excision combined with irradiation." | ( Brunstein, F; de Wilt, JH; Eggermont, AM; Graveland, WJ; Grünhagen, DJ; van Geel, AN, 2005) |
| "Forty-nine patients with pretreated soft tissue sarcoma (the STS arm) and 18 patients with previously untreated gastrointestinal stromal tumor (the GIST arm) were enrolled onto a 2-arm, multicenter, Phase II study between November 1999 and July 2001." | ( Bover, I; Buesa, JM; Casado, A; Cruz, J; Garcia del Muro, X; Lopez-Pousa, A; Martin, J; Martinez-Trufero, J; Maurel, J; Poveda, A, 2005) |
| "Both patients with soft tissue sarcoma (STS) and patients with melanoma have limited treatment possibilities once the tumor has metastasized systemically." | ( de Wilt, JH; Eggermont, AM; Graveland, WJ; Grunhagen, DJ; van Geel, AN, 2006) |
| "Two children with soft tissue sarcomas receiving etoposide as part of their standard clinical treatment had external biliary drainage due to obstruction of the bile duct." | ( Boddy, AV; Errington, J; Lowis, S; Thomas, HD; Veal, GJ, 2006) |
| "Patients with soft tissue sarcomas of the head and neck, extremity, trunk, or retroperitoneum for whom surgical excision was the initial treatment of choice, were given 21 mg/kg EF5 24-48 hours before surgery." | ( Evans, SM; Fraker, D; Gleason, K; Hahn, SM; Hwang, WT; Jenkins, K; Jenkins, WT; Koch, CJ; Mick, R; Zhang, P, 2006) |
| "Thirty-two patients with soft tissue sarcoma were treated with CT-guided argon-helium cryoablation." | ( Li, LJ; Song, Q; Zhan, Y, 2006) |
| "The treatment of soft tissue sarcomas includes different modalities, but the complete excision of the tumor is the most important one." | ( Schmidt, A; Voigtländer, D, 2006) |
| "Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy." | ( Abdel-Rahman, S; Baumert, J; Falk, M; Hentrich, M; Hiddemann, W; Issels, RD; Licht, T; Salat, C; Schlemmer, M; Straka, C; Wendtner, CM, 2006) |
| "Bone and soft tissue sarcomas represent rare tumors that can be cured by local treatment at early stages of disease." | ( Mita, MM; Tolcher, AW, 2007) |
| "For patients with advanced soft tissue sarcoma (STS), no standard treatment is established after previous chemotherapy with anthracyclines and ifosfamide." | ( Grünwald, V; Hartmann, JT; Horger, M; Huober, J; Käfer, G; Kanz, L; Mayer, F; Meisinger, I; Pintoffl, J; Schleicher, J, 2007) |
| "Metastasizing epithelioid sarcoma (ES) is an extremely aggressive tumor, because conventional chemotherapy and irradiation are largely ineffective." | ( Gabbert, HE; Grinstein, E; Haremza, J; Heikaus, S; Mahotka, C; Matuszek, KS; Ramp, U; Reinecke, P; Suschek, CV, 2008) |
| "The response of adult soft tissue sarcoma (STS) to chemotherapy is uncertain." | ( Guan, ZZ; Huang, HQ; Jiang, WQ; Li, FH; Lin, TY; Luo, HY; Qiu, MZ; Sun, XF; Wang, F; Wang, SS; Xu, F; Xu, GC; Xu, RH, 2007) |
| "Clinical data of 109 adult soft tissue sarcoma patients, treated with chemotherapy at Cancer Center of Sun Yat-sen University from Jan." | ( Guan, ZZ; Huang, HQ; Jiang, WQ; Li, FH; Lin, TY; Luo, HY; Qiu, MZ; Sun, XF; Wang, F; Wang, SS; Xu, F; Xu, GC; Xu, RH, 2007) |
| "Advanced stage/metastatic soft tissue sarcoma (STS) has a poor prognosis especially after failure of the established first-line treatment." | ( Bauer, S; Ebeling, P; Eisele, L; Flasshove, M; Moritz, T; Schuett, P; Schuette, J; Seeber, S, 2008) |
| "Thirty-five patients with bone and soft tissue sarcoma treated with carbon ion beams were studied." | ( Imai, R; Kamada, T; Serizawa, I; Tsuji, H; Tsujii, H; Yanagi, T, 2010) |
| "Adult patients with advanced soft tissue sarcomas (STS) are generally treated similarly, regardless of great differences between STS subtypes, disease presentation and patients' characteristics." | ( Blay, JY; Hogendoorn, PC; Krarup-Hansen, A; Le Cesne, A; Ouali, M; Rodenhuis, S; Sleijfer, S; van Glabbeke, M; Verweij, J, 2010) |
| "Grading of soft tissue sarcomas is an important prerequisite for the choice of therapy and estimation of prognosis." | ( Choe, JG; Kang, CH; Kim, CH; Noh, W; Park, EK; Park, JH, 2009) |
| "In patients with bone and soft tissue sarcomas, preoperative chemotherapy is essential and the early prediction of the tumor response to chemotherapy would be beneficial for the planning of treatment strategy." | ( Inaki, A; Kinuya, S; Sumiya, H; Taki, J; Tsuchiya, H; Wakabayashi, H; Zen, Y, 2010) |
| "Seventy-three patients with bone and soft tissue sarcomas underwent Tc-99m-MIBI scintigraphy before chemotherapy and at least 2 times after the second or third or fifth course of chemotherapy." | ( Inaki, A; Kinuya, S; Sumiya, H; Taki, J; Tsuchiya, H; Wakabayashi, H; Zen, Y, 2010) |
| "In patients with bone and soft tissue sarcomas, the change of Tc-99m-MIBI images from prechemotherapy to early to middle of chemotherapy can predict the final histopathological tumor response to chemotherapy as accurately as the change of Tc-99m-MIBI images from prechemotherapy to the completion of the preoperative chemotherapy." | ( Inaki, A; Kinuya, S; Sumiya, H; Taki, J; Tsuchiya, H; Wakabayashi, H; Zen, Y, 2010) |
| "For patients with primary bone and soft tissue sarcomas FDG-PET/CT is utilized for diagnosis, staging and restaging, metabolic tumor grading, guidance of biopsies, detection of tumor recurrence and therapy monitoring." | ( Berger, F; Issels, R; Reiser, MF; Rist, C; Schlemmer, M; Schramm, N, 2010) |
| "In our department, 20 patients with soft tissue sarcomas of the hand/forearm were treated between 1995 and 2005." | ( Bickert, B; Germann, G; Sauerbier, M; Vetter, M, 2010) |
| "Adjuvant chemotherapy for grade 2 and 3 soft tissue sarcoma (STS) patients still has to be considered experimental." | ( Abdolvahab, F; Brodowicz, T; Dominkus, M; Ebm, C; Fakhrai, N; Jantsch, M; Kauer-Dorner, D; Kostler, WJ; Pokrajac, B; Zielinski, CC, 2010) |
| "Standard treatment for localized soft tissue sarcoma (STS) is resection plus adjuvant radiotherapy (RTx)." | ( Burger, JW; de Jong, JS; den Bakker, MA; Deroose, JP; Eggermont, AM; van Geel, AN; Verhoef, C, 2011) |
| "Twenty-one epithelioid sarcoma patients treated with chemotherapy were identified; follow-up data on palliative chemotherapy was available on 20 of these patients." | ( Al-Muderis, O; Constantinidou, A; Fisher, C; Jones, RL; Judson, IR; Olmos, D; Scurr, M; Thway, K, 2012) |
| "Bone and soft tissue sarcomas are rare, heterogeneous tumors that are curable by local treatments if diagnosed at early stages; however advanced or metastatic sarcomas are rarely curable and very few drugs are efficacious in this setting." | ( Alvarado, Y; Mita, A; Mita, M; Sankhala, K; Vemulapalli, S, 2011) |
| "For patients with refractory bone and soft tissue sarcoma (STS), treatment options have been limited." | ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011) |
| "To determine safe surgical margins for soft tissue sarcoma, it is essential to perform a general evaluation of the extent of tumor, responses to auxiliary therapy, and other factors preoperatively using multiple types of diagnostic imaging." | ( Arishima, Y; Komiya, S; Nagano, S; Tanimoto, A; Terahara, M; Yokouchi, M; Yoshioka, T; Zemmyo, M, 2011) |
| "The role of chemotherapy in high-risk soft tissue sarcoma is controversial." | ( Bischof, M; Dietrich, S; Dimitrakopoulou-Strauss, A; Egerer, G; Ho, AD; Kasper, B; Lehner, B; Mechtersheimer, G; Roeder, F; Schmitt, T; Strauss, LG; Wuchter, P, 2011) |
| "We treated 170 patients with high-grade soft tissue sarcoma between 1999 and 2009." | ( Kusuzaki, K; Matsubara, T; Matsumine, A; Nakamura, T; Sudo, A, 2013) |
| "Human soft tissue sarcomas represent a rare group of malignant tumours that frequently exhibit chemotherapeutic resistance and increased metastatic potential following unsuccessful treatment." | ( Bauer, R; Boechzelt, H; Kaltenegger, H; Kretschmer, N; Kunert, O; Leithner, A; Lohberger, B; Rinner, B; Stuendl, N; Wolf, E, 2012) |
| "Locally advanced, limb threatening soft tissue sarcomas (STS) pose a significant treatment challenge." | ( Bui, MM; Cheong, D; Conley, A; Gonzalez, RJ; Letson, DG; Reed, D; Turaga, KK; Vohra, NA; Zager, JS, 2013) |
| "Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9." | ( Badalamenti, G; Bronte, G; Fulfaro, F; Incorvaia, L; Leto, G; Maltese, G; Provenzano, S, 2013) |
| "As treatment results for high-risk soft tissue sarcoma are still disappointing, treatment intensification is warranted." | ( Bamberg, M; Eckert, F; Gani, C; Kluba, T; Kopp, HG; Mayer, F; Müller, AC; Zips, D, 2013) |
| "Treatment of advanced soft tissue sarcoma remains a considerable therapeutic challenge." | ( Reichardt, P, 2013) |
| "Historically, treatment options for soft tissue sarcoma in adults have been limited." | ( Blay, JY, 2013) |
| "Standard treatment for soft tissue sarcoma of the extremity is surgical excision and adjuvant therapy; however, the role of neoadjuvant chemotherapy is controversial." | ( Cheng, EY; Clohisy, DR; Manivel, JC; O'Donnell, PW, 2014) |
| "Non-gastrointestinal stromal soft tissue sarcomas are uncommon neoplasms that have a dismal prognosis due to a high incidence of metastases and a poor response to conventional chemotherapy." | ( Jagannathan, JP; Kim, KW; Krajewski, KM; O'Regan, K; Ramaiya, NH; Shinagare, AB; Tirumani, SH, 2013) |
| "Sixteen cases of malignant soft tissue sarcoma (STS; 10 canines and six felines) were treated with a novel triple therapy that combined photodynamic therapy, hyperthermia using indocyanine green with a broadband light source, and local chemotherapy after surgical tumor resection." | ( Azuma, K; Imagawa, T; Ishi, H; Kawashima, K; Minami, S; Ogawa, N; Okamoto, Y; Onoyama, M; Osaki, T; Takayama, T; Tsuka, T, 2014) |
| "Chemotherapy for soft tissue sarcomas remains unsatisfactory due to their low chemosensitivity." | ( Al-Benna, S; Junge, CG; Liffers, ST; Mirmohammadsadegh, A; Steinau, HU; Stricker, I; Tannapfel, A; Tilkorn, DJ; Tischoff, I; Verdoodt, B; Vogt, M, 2013) |
| "Patients with high-grade soft tissue sarcomas were treated with 2 cycles of ifosfamide, mitomycin, doxorubicin, and cisplatin plus GM-CSF subcutaneous followed by 45 Gy irradiation with concurrent 2 cycles of mitomycin, doxorubicin, and cisplatin followed by surgery +/- intraoperative radiation or brachytherapy." | ( Haddock, M; Mahoney, M; Maples, W; Markovic, SN; O'Connor, MI; Okuno, S; Petersen, I; Shives, T; Sim, F, 2016) |
| "As adjuvant chemotherapy (AC) for soft tissue sarcomas is controversial, we performed a retrospective analysis of patients seen at Washington University in St." | ( Adkins, DR; Luo, J; Montgomery, L; Morgensztern, D; Schenone, AD; Van Tine, BA, 2014) |
| "This review focuses on soft tissue sarcoma and covers general topics such as the epidemiology, age distribution, site of disease, histogenesis, histological subtypes, prognosis and outcome of treatment." | ( Cornillie, J; Hompes, D; Li, H; Schöffski, P; Wozniak, A, 2014) |
| "The outcome for patients with metastatic soft tissue sarcoma is poor with few available systemic treatment options." | ( Jones, RL; Loggers, ET; Petek, BJ; Pollack, SM, 2015) |
| "For extremity soft tissue sarcomas (STS), surgical resection remains the standard of care, and the addition of chemotherapy is controversial." | ( Agulnik, M; Carvajal, RD; Chi, P; Chmielowski, B; Crago, AM; D'Angelo, SP; Dickson, MA; Ezeoke, MO; Gounder, MM; Hameed, M; Healey, JH; Keohan, ML; Landa, J; Luke, JJ; Munhoz, RR; Qin, LX; Schwartz, GK; Singer, S; Singh, AS; Tap, WD; Van Tine, BA, 2015) |
| "Neoadjuvant chemoradiotherapy for soft tissue sarcoma is associated with good feasibility, manageable acute and late toxicities, and high local efficacy." | ( Agaimy, A; Croner, R; Fietkau, R; Hohenberger, W; Lettmaier, S; Ott, O; Semrau, S; Stubbe, F; Vassos, N, 2016) |
| "For resectable soft tissue sarcoma (STS), radical surgery, usually combined with radiotherapy, is the mainstay of treatment and the only potentially curative modality." | ( Attenberger, U; Derigs, HG; Dimitrakopoulou-Strauss, A; Egerer, G; Fröhling, S; Gaiser, T; Hohenberger, P; Jakob, J; Kasper, B; Nowak, K; Pilz, LR; Ronellenfitsch, U; Schwarzbach, M, 2016) |
| "The European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) conducted a multinational prospective study of registered cases of extracranial MRT to test an intensive multimodal approach of treatment for children with newly diagnosed extracranial MRT." | ( Bisogno, G; Brennan, B; Casanova, M; De Paoli, A; De Salvo, GL; Ferrari, A; Francotte, N; Kelsey, A; Mudry, P; Orbach, D; Van Noesel, M, 2016) |
| "Between 06/10 and 09/13, 40 Soft Tissue Sarcoma patients were treated with vorinostat at seven participating centres." | ( Burhenne, J; Egerer, G; Grünwald, V; Hajda, J; Hartmann, JT; Heilig, CE; Ho, AD; Hüsing, J; Kasper, B; Lehmann, L; Mayer, F; Mayer-Steinacker, R; Mechtersheimer, G; Mikus, G; Ottawa, G; Schmitt, T; Schütte, J, 2016) |
| "It is approved for the treatment of Soft Tissue sarcomas (STS) in Europe and recently by the FDA for liposarcomas and leiomyosarcomas." | ( von Mehren, M; Zijoo, R, 2016) |
| "Treatment-resistant, locally advanced soft tissue sarcomas often require amputation for complete tumor extirpation." | ( Bhati, R; Chen, YA; Farma, JM; Gonzalez, RJ; Hardmann, D; Kroon, HM; Mosca, PJ; Mullinax, JE; Naqvi, SM; Nath, N; O'Donoghue, C; Perez, M; Sileno, S; Thompson, JF; Zager, JS, 2017) |
| "Research into the biology of soft tissue sarcomas has uncovered very few effective treatment strategies that improve upon the current standard of care which usually involves surgery, radiation, and chemotherapy." | ( Alexander, A; Bui, T; Francis, AM; Hunt, KK; Keyomarsi, K; Liu, Y; Low, KH; Ravi, V; Somaiah, N; Vijayaraghavan, S; Yang, D, 2017) |
| "In the treatment of metastatic soft tissue sarcoma (STS), pazopanib is considered a standard treatment after failure of chemotherapy." | ( Kim, HJ; Kim, Y; Lee, J; Lee, SJ; Park, SH, 2018) |
| "Patients with soft tissue sarcoma are at risk for local recurrence and distant metastases despite optimal local treatment." | ( Abdel-Rahman, S; Angele, M; Belka, C; Daugaard, S; Dürr, HR; Ghadjar, P; Gronchi, A; Hiddemann, W; Hohenberger, P; Issels, RD; Jauch, KW; Knösel, T; Lindner, LH; Mansmann, U; Mella, O; Reichardt, P; Salat, C; Schmidt, M; Verweij, J; Vujaskovic, Z; Wessalowski, R; Wust, P, 2018) |
| "Among patients with localized high-risk soft tissue sarcoma the addition of regional hyperthermia to neoadjuvant chemotherapy resulted in increased survival, as well as local progression-free survival." | ( Abdel-Rahman, S; Angele, M; Belka, C; Daugaard, S; Dürr, HR; Ghadjar, P; Gronchi, A; Hiddemann, W; Hohenberger, P; Issels, RD; Jauch, KW; Knösel, T; Lindner, LH; Mansmann, U; Mella, O; Reichardt, P; Salat, C; Schmidt, M; Verweij, J; Vujaskovic, Z; Wessalowski, R; Wust, P, 2018) |
| "Patients with recurrent or metastatic soft tissue sarcoma, consecutively observed at our institution, who were considered eligible to trabectedin, received concomitant NAC if they had impaired hepatic or renal function at baseline or developed hepatotoxicity during treatment." | ( Berruti, A; Bianchi, S; Consoli, F; Cosentini, D; Ferrari, VD; Grisanti, S; Lazzari, B; Roca, E; Tovazzi, V, 2018) |
| "Systemic treatment options for soft tissue sarcomas (STSs) have remained unchanged despite the need for novel drug candidates to improve STS outcomes." | ( Chen, G; He, RQ; Huang, WT; Liu, AG; Ma, J; Wu, HY; Yang, X, 2019) |
| "Patients with localized high-risk soft tissue sarcoma are at high risk for both local recurrence and distant metastases despite optimal surgical treatment." | ( Lindner, LH, 2019) |
| "For high-risk soft tissue sarcomas, multimodal treatment strategies involving perioperative chemotherapy, radiotherapy and, if possible, hyperthermia should be considered in addition to tumor resection." | ( Lindner, LH, 2019) |
| "Paediatric soft tissue sarcoma treatments and outcomes have improved significantly in the last few decades." | ( Banavali, S; Devadas, SK, 2019) |
| "Although eribulin is used to treat soft tissue sarcomas (STSs), treatment data for rare subtypes are limited." | ( Asano, N; Endo, M; Kawai, A; Kobayashi, E; Maejima, A; Megumi, Y; Naito, Y; Takahashi, S, 2019) |
| "Although 40% of cases of soft tissue sarcoma (STS) are diagnosed in patients aged ≥65 years, this group is largely excluded from or under-represented in clinical trials and receives disproportionately less treatment than younger patients." | ( Jones, RL, 2019) |
| "Treatment goals for advanced soft tissue sarcoma (STS) vary according to disease stage and treatment line." | ( Hindi, N; Martin-Broto, J; Moura, DS, 2019) |
| "Radiotherapy for soft tissue sarcomas (STS) of the hand is thought to be associated with poor function." | ( Ahmed, SK; Bakri, K; Houdek, MT; Logli, AL; Moran, SL; Munaretto, NF; Petersen, IA; Rose, PS, 2020) |
| "We compared the outcomes in soft tissue sarcoma (STS) treated with olaratumab and doxorubicin (OD) versus doxorubicin, ifosfamide, and mesna (AIM) to assess whether OD could supersede AIM in STS therapy." | ( Copeland, VC; Cranmer, LD; Hammer, KJ; Loggers, ET; Pollack, SM; Wagner, MJ, 2020) |
| "Standard chemotherapy for soft tissue sarcomas has shown limited efficacy." | ( Azzariti, A; Di Fonte, R; Fucci, L; Garofoli, M; Guida, M; Porcelli, L; Strippoli, S; Volpicella, M, 2020) |
| "The value of chemotherapy in soft tissue sarcoma (STS) remains controversial." | ( Cabarrou, B; Chevreau, C; Chibon, F; Filleron, T; Le Guellec, S; Lesluyes, T; Lodin, S; Massoubre, A; Mounier, M; Poublanc, M; Valentin, T, 2020) |
| "The choice of drug treatment in advanced soft tissue sarcoma (STS) continues to be a challenge regarding efficacy, quality of life (QoL) and toxicity." | ( Arndt, K; Bornhäuser, M; Chemnitz, JM; Freitag, J; Grünwald, V; Hentschel, L; Hornemann, B; Kasper, B; Kessler, T; Kopp, HG; Kunitz, A; Pelzer, U; Richter, S; Schilling, A; Schuler, MK; Schuler, U, 2020) |
| "In metastatic soft tissue sarcoma systemic therapy is the treatment of choice." | ( Pink, D; Reichardt, P, 2021) |
| "In the first-line setting of advanced soft tissue sarcomas (STS), the treatment aim generally drives decision-making." | ( Broto, JM; Jones, RL, 2021) |
| "It is extremely rare in the treatment of soft tissue sarcoma (STS) of the limbs or trunk, and there are currently no reports of TLS occurrence from eribulin therapy." | ( Miyakoshi, N; Nagasawa, H; Shimada, Y; Tsuchie, H, 2021) |
| "The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not completely understood." | ( Bagué, S; Bianchi, G; Blay, JY; Braglia, L; Brunello, A; Bruzzi, P; Casali, PG; Coindre, JM; Dei Tos, AP; Diaz-Beveridge, R; Donati, DM; Ferraresi, V; Fontana, V; Grignani, G; Gronchi, A; Infante, G; Lopez-Pousa, A; Lugowska, I; Marchesi, E; Marrari, A; Martin-Broto, J; Merlo, DF; Miceli, R; Morosi, C; Palassini, E; Palmerini, E; Pasquali, S; Picci, P; Quagliuolo, V; Stacchiotti, S; Tendero, O, 2022) |
| "In cases of soft tissue sarcoma (STS), neoadjuvant therapy is indicated to downstage the tumour prior to surgery to achieve enhanced local tumour control." | ( de Campos Fonseca Pinto, ACB; de Castro, PF; Maria, DA; Matera, JM; Patricio, GCF, 2022) |
| "The records of bone and soft tissue sarcoma patients treated at our institution were reviewed." | ( Batus, M; Blank, AT; Colman, MW; Gitelis, S; Kazmer, A; Lee, L, 2022) |
| "For first-line treatment of advanced soft tissue sarcoma in elderly patients, doxorubicin monotherapy is considered to be the standard regimen, and pazopanib can be an alternative." | ( Ozaki, T; Tanaka, K, 2022) |
| "Chemotherapy of soft tissue sarcomas (STS) is restricted by low chemosensitivity and multiple drug resistance (MDR)." | ( Belitsky, GA; Bokhyan, BY; Burov, DA; Fetisov, TI; Fomina, LY; Kirilin, EM; Kirsanov, KI; Kozlov, NA; Laletina, LA; Lesovaya, EA; Makhmudova, LF; Manikaylo, AE; Mekheda, LV; Moiseeva, NI; Scherbakov, AM; Vilkova, AS; Yakubovskaya, MG; Zinovieva, VY, 2022) |
| "The standard of care treatment for soft tissue sarcoma of the extremities is a wide resection in combination with pre- or postoperative radiotherapy with high local control rates, sparing patients the necessity of amputation without compromising on overall survival rates." | ( Brügemann, D; Debus, J; Egerer, G; Geisbüsch, A; Harrabi, SB; Herfarth, K; Hommertgen, A; Jaekel, C; Kieser, M; Krisam, J; Lehner, B; Mechtesheimer, G; Sedlaczek, O; Seidensaal, K; Uhl, M, 2022) |
| "Some cancers such as sarcomas (bone and soft tissue sarcomas) and adenoid cystic carcinomas are considered as radioresistant to low linear energy transfer radiation (including photons and protons) and may therefore beneficiate from a carbon ion therapy." | ( Akkal, Z; Allemand, H; Alloh, AS; Balosso, J; Bono, C; Chabaud, S; Cornu, C; Febvey-Combes, O; Fiore, MR; Guerre, P; Gueyffier, F; Hervé, M; Iung, A; Lièvre, M; Lozano, H; Margier, J; Orecchia, R; Patin, S; Plattner, V; Pommier, P; Valvo, F; Vischioni, B; Vitolo, V, 2022) |
| "The therapy of high-risk soft tissue sarcomas (STS) remains an interdisciplinary challenge." | ( Ademaj, A; Corradini, S; Eckert, F; Flörcken, A; Ghadjar, P; Issels, R; Kaul, D; Lindner, LH; Oberacker, E; Ott, OJ; Pink, D; Potkrajcic, V; Reichardt, P; Riesterer, O; Roohani, S; Spalek, MJ; Veltsista, PD; Zips, D, 2023) |
| "Treatment of highly malignant soft tissue sarcomas (STSs) requires multicomponent therapy including surgery, radiotherapy, and chemotherapy." | ( Anastasia, TA; Belitsky, GA; Bokhyan, BY; Fetisov, TI; Khazanova, SA; Kirsanov, KI; Lovenger, AA; Marshall, VI; Rogozhin, DV; Shtompel, PA; Trapeznikova, ES; Yakubovskaya, MG; Zinovieva, VY, 2023) |
| "The better understanding of soft tissue sarcoma (STS) pathophysiology and disease course has led to the development of adapted clinical trial designs for rare STS histotypes with specific treatment approach." | ( Assi, T; Bahleda, R; Faron, M; Hénon, C; Honoré, C; Le Cesne, A; Le Péchoux, C; Lévy, A; Ngo, C; Verret, B, 2023) |